Highlights for August 2017
- Strides complete acquisition of Australia Business of Amneal Pharma
- India's Aurobindo Pharma, Intas in race to buy Mallinckrodt's US generic business
- Daiichi sankyo enters worldwide licensing agreement with Boston pharmaceuticals for a highly selective RET inhibitor for solid tumors
- Astrazeneca, Takeda ink Parkinson’s co-development deal
- CSL Behring buys Calimmune for early stem cell, gene therapy boost
- Jazz pays $75M for chance to buy into immunogen adcs
- Samsung jumps into novel drug R&D through Takeda deal
- Regenxbio to buy battered Dimension for gene therapies
- Chinese biotechs sign extensive I-O deal with Arcus Biosciences worth up to $816 million
- Mundipharma and cellact announce new deal for the worldwide development and commercialization of smart chemotherapy CAP7.1
- Bile duct cancer candidate bought by Mundipharma in deal worth up to $250 million
- Dermira gains certain rights to Roche mab in up to $1.4 billion deal
- Takeda and cardurion pharmaceuticals launch cardiovascular development partnership
- Tesaro and takeda enter into exclusive licensing agreement to develop and commercialize novel cancer therapy niraparib in japan
- China’s hitgen bags new drug discovery deal with Aduro
For more such news and updates, please join our Group "Global Life Science Business Partnering" on LinkedIn.